StreetInsider.com News Articles

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

Wed, 11 Mar 2026 02:00:00 -0400

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations.
During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio.
Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus‑based CGM competency framework to give healthcare professionals a clear, role‑aligned structure for delivering confident, consistent CGM support.2

BARCELONA, Spain--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM),

Wed, 11 Mar 2026 02:00:00 -0400

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations.
During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio.
Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus‑based CGM competency framework to give healthcare professionals a clear, role‑aligned structure for delivering confident, consistent CGM support.2

BARCELONA, Spain--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM),

Wed, 11 Mar 2026 02:00:00 -0400

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations.
During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio.
Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus‑based CGM competency framework to give healthcare professionals a clear, role‑aligned structure for delivering confident, consistent CGM support.2

BARCELONA, Spain--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM),

Wed, 11 Mar 2026 02:00:00 -0400

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy1, reinforcing the need to broaden CGM access beyond insulin-treated populations.
During its symposium on Thursday, March 12, Dexcom will share upcoming product features across its global portfolio.
Two in-booth, expert-led presentations on Thursday, March 12, and Friday, March 13 will showcase the first consensus‑based CGM competency framework to give healthcare professionals a clear, role‑aligned structure for delivering confident, consistent CGM support.2

BARCELONA, Spain--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM),